Biotricity Inc.
BTCY Healthcare Medical Devices
Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025. In the quarter to June 2026, revenue grew 10.4%, EPS fell 66.7%, free cash flow grew 235.8% and total debt rose 3.48%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow BTCY
Biotricity Inc. (BTCY) Altman Z-score
Biotricity Inc.'s Altman Z-score for fiscal 2026 is −33.34, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | −33.34 | 3.54 |
| FY2025 | −36.88 | (0.50) |
| FY2024 | −36.38 | (5.20) |
| FY2023 | −31.17 | (24.55) |
| FY2022 | −6.62 | 19.24 |
| FY2021 | −25.86 | 20.89 |
| FY2020 | −46.76 | 106.58 |
| FY2019 | −153.33 | — |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (4.85) | — | −5.82 | |
| Retained earnings / total assets | (22.12) | — | −30.96 | |
| EBIT / total assets | 0.26 | — | 0.87 | |
| Market value of equity / total liabilities | 0.16 | — | 0.09 | |
| Sales / total assets | 2.48 | — | 2.48 | |
| Altman Z-score | Distress zone | −33.34 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −103.06 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| IRIX IRIDEX Corporation compare | −2.0× |
| NMTC NeuroOne Medical Technologies Corporation compare | −3.7× |
| CTSO Cytosorbents Corporation compare | −9.2× |
| AEMD Aethlon Medical, Inc. compare | −10.8× |
| BMRA Biomerica, Inc. compare | −12.4× |
| BTCY Biotricity Inc. | −33.3× |
| PETV PetVivo Holdings, Inc. compare | −38.6× |
| SINT SINTX TECHNOLOGIES, INC. compare | −45.4× |
| RBOT Vicarious Surgical Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets